Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 19;22(20):11258.
doi: 10.3390/ijms222011258.

Functional Depletion of HSP72 by siRNA and Quercetin Enhances Vorinostat-Induced Apoptosis in an HSP72-Overexpressing Cutaneous T-Cell Lymphoma Cell Line, Hut78

Kazuyasu Fujii  1 , Masashi Idogawa  2 , Norihiro Suzuki  3 , Keiji Iwatsuki  3 , Takuro Kanekura  1
Affiliations

Functional Depletion of HSP72 by siRNA and Quercetin Enhances Vorinostat-Induced Apoptosis in an HSP72-Overexpressing Cutaneous T-Cell Lymphoma Cell Line, Hut78

Kazuyasu Fujii et al. Int J Mol Sci. .

Abstract

Histone deacetylase inhibitors (HDACis) are one of the therapeutic options for cutaneous T-cell lymphoma (CTCL), but they have limited effects. We previously demonstrated that HSP72 overexpression is associated with chemoresistance to HDACis in lymphoma cells. The purpose of this study was to investigate whether the functional depletion of HSP72 enhances the effect of the HDACi vorinostat. First, we established a stable HSP72-knockdown CTCL cell line and confirmed the influence of HSP72 reduction on the antitumor effects of vorinostat. Next, we studied the effect of quercetin, an inhibitor of HSP72, on the antineoplastic effects of vorinostat. In five CTCL cell lines examined, HSP72 expression was highest in Hut78 cells, and HSP72 knockdown enhanced vorinostat-induced apoptosis in these cells. Low-dose quercetin reduced HSP72 expression, increased HDAC activity, and enhanced vorinostat-induced suppression of Hut78 cell proliferation. A single low dose of quercetin induced G2 arrest and only slightly increased the sub-G1 cell fraction. Quercetin also significantly enhanced vorinostat-induced apoptosis, caspase-3, caspase-8, and caspase-9 activity, and the loss of mitochondrial membrane potential. HSP72 knockdown enhanced vorinostat-induced apoptosis in an HSP72-overexpressing CTCL cell line, and thus, quercetin may be a suitable candidate for combination therapy with vorinostat in clinical settings.

Keywords: HSP72; combination therapy; cutaneous T-cell lymphoma; histone deacetylase inhibitor; quercetin.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

Figures

Figure 1
Figure 1
Expression of HSP72 protein in five cutaneous T-cell lymphoma (CTCL) cell lines. Expression of HSP72 in each cell line was described as the relative mean fluorescence intensity (rMFI) + SD (n = 3).
Figure 2
Figure 2
Characterization of HSP72-knockdown Hut78 cells. HSP72 mRNA expression for MOCK (gray bar) and HSP72-knockdown (black bar) Hut78 cells, normalized to GAPDH expression levels ((a), n = 2). Flow cytometric analysis of HSP72 protein expression in MOCK (gray bar) and HSP72 knockdown (black bar) cells, showing the relative mean fluorescence intensity (rMFI) + SD ((b), n = 3). Proliferation assay with vorinostat using the WST-1 assay kit ((c), n = 4). ◆: MOCK, and ■: HSP72 knockdown Hut78 cells. Assessment of the influence of HSP72 knockdown on the antitumor effects of vorinostat. Representative images are shown in the left panels, and the summary is shown in the right panel (d). Assessment of apoptosis by annexin-V assays (e). * p < 0.05, ** p < 0.01, by student t-test.
Figure 3
Figure 3
Influence of quercetin on vorinostat-treated Hut78 cells. Cell proliferation was assessed by WST-1 assays ((a), n = 4). ◆: treated by vorinostat, ■: quercetin, and ○: both vorinostat and quercetin (1:40). HSP72 protein expression was measured via FACS (b). HDAC activity was assessed by the HDAC-Glo™ I/II Assays and adjusted with the CellTiter-FluorTM Cell Viability Assay (c). Acetylated lysin (d) and acetylated histone H3 (e) were measured via FACS. * p < 0.05, ** p < 0.01 by Bonferroni t-test.
Figure 4
Figure 4
Assessment of the effect of quercetin on the antitumor effects of vorinostat in Hut78 cells. Propidium iodide staining (a). Representative images are shown in the left panels and the summary of the analysis is shown as a bar graph in the right panel. Annexin V assay (b); cleaved PARP assay (c); activated caspase-3/7 (d), caspase-9 (e), and caspase-8 (h) analysis; loss of mitochondrial membrane potential (f); bcl-XL expression (g) as assessed via FACS. * p < 0.05, ** p < 0.01 by Bonferroni t-test.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Swerdlow S.H., Campo E., Pileri S.A., Harris N.L., Stein H., Siebert R., Advani R., Ghielmini M., Salles G.A., Zelenetz A.D., et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390. doi: 10.1182/blood-2016-01-643569. - DOI - PMC - PubMed
    1. Scarisbrick J.J., Kim Y.H., Whittaker S.J., Wood G.S., Vermeer M.H., Prince H.M., Quaglino P. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sezary syndrome: Where are we now? Br. J. Dermatol. 2014;170:1226–1236. doi: 10.1111/bjd.12909. - DOI - PubMed
    1. Hughes C.F., Khot A., McCormack C., Lade S., Westerman D.A., Twigger R., Buelens O., Newland K., Tam C., Dickinson M., et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: A comparative study of systemic therapy. Blood. 2015;125:71–81. doi: 10.1182/blood-2014-07-588236. - DOI - PubMed
    1. Akilov O.E., Geskin L. Therapeutic advances in cutaneous T-cell lymphoma. Skin Ther. Lett. 2011;16:1–5. - PMC - PubMed
    1. Blaizot R., Ouattara E., Fauconneau A., Beylot-Barry M., Pham-Ledard A. Infectious events and associated risk factors in mycosis fungoides/Sezary syndrome: A retrospective cohort study. Br. J. Dermatol. 2018;179:1322–1328. doi: 10.1111/bjd.17073. - DOI - PubMed

MeSH terms